A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.

Antimicrob Agents Chemother · 2022 · PMC9578433 · PMID 36098519

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with mild-to-moderate COVID-19 who were treated with ensitrelvir showed a trend of symptom relief.

also in 53,322 other papers

a decreasing trendno p-value reported

The mean total score of the predefined 12 symptoms in patients with mild-to-moderate COVID-19 showed a decreasing trend with time after treatment initiation in all groups ( Fig. 4A ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.